[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 187
Citations 0
From JAMA's Daily News Site
July 10, 2013

From JAMA’s Daily News Site

JAMA. 2013;310(2):132. doi:10.1001/jama.2013.8331

Intravenous immunoglobulin (IVIG [Gammagard]) did not reduce cognitive decline or preserve functional abilities in patients with mild to moderate Alzheimer disease, according to a phase 3 randomized trial.

The trial enrolled 390 patients at 45 centers across the United States and Canada. Participants received IVIG or placebo every 2 weeks for 18 months. The study results did not show a statistically significant difference in the rate of cognitive decline or functional ability for those receiving IVIG compared with placebo.